Decision Diagnostics DECN Stock
Decision Diagnostics Price Chart
Decision Diagnostics DECN Financial and Trading Overview
Decision Diagnostics stock price | 0.0001 USD |
Previous Close | 0.0001 USD |
Open | 0.0001 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 0.0001 - 0.0001 USD |
52 Week Range | 0.0001 - 0.0004 USD |
Volume | 38.7K USD |
Avg. Volume | 32.78K USD |
Market Cap | 35.79K USD |
Beta (5Y Monthly) | -0.938028 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.02 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
DECN Valuation Measures
Enterprise Value | 3.17M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.016797466 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 1.489 |
Enterprise Value/EBITDA | N/A |
Trading Information
Decision Diagnostics Stock Price History
Beta (5Y Monthly) | -0.938028 |
52-Week Change | -66.66% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.0004 USD |
52 Week Low | 0.0001 USD |
50-Day Moving Average | 0.0001 USD |
200-Day Moving Average | 0.0001115 USD |
DECN Share Statistics
Avg. Volume (3 month) | 32.78K USD |
Avg. Daily Volume (10-Days) | 118.06K USD |
Shares Outstanding | 357.87M |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1.1:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2020 |
Most Recent Quarter (mrq) | September 30, 2021 |
Next Fiscal Year End | December 31, 2021 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -90.70% |
Gross Margin | 21.69% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -21.21% |
Return on Equity (ttm) | -8160.51% |
Income Statement
Revenue (ttm) | 2.13M USD |
Revenue Per Share (ttm) | 0.006 USD |
Quarterly Revenue Growth (yoy) | -0.40% |
Gross Profit (ttm) | 194.17K USD |
EBITDA | N/A |
Net Income Avi to Common (ttm) | -8288395 USD |
Diluted EPS (ttm) | -0.02 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 210.85K USD |
Total Cash Per Share (mrq) | 0.001 USD |
Total Debt (mrq) | 3.35M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.247 |
Book Value Per Share (mrq) | 0 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1037808 USD |
Levered Free Cash Flow (ttm) | -1128809 USD |
Profile of Decision Diagnostics
Country | United States |
State | CA |
City | Westlake Village |
Address | 2660 Townsgate Road |
ZIP | 91361 |
Phone | 805 446 1973 |
Website | https://www.decisiondiagnostics.co |
Industry | Pharmaceutical Retailers |
Sector(s) | Healthcare |
Full Time Employees | 6 |
Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.
Q&A For Decision Diagnostics Stock
What is a current DECN stock price?
Decision Diagnostics DECN stock price today per share is 0.0001 USD.
How to purchase Decision Diagnostics stock?
You can buy DECN shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Decision Diagnostics?
The stock symbol or ticker of Decision Diagnostics is DECN.
Which industry does the Decision Diagnostics company belong to?
The Decision Diagnostics industry is Pharmaceutical Retailers.
How many shares does Decision Diagnostics have in circulation?
The max supply of Decision Diagnostics shares is 357.87M.
What is Decision Diagnostics Price to Earnings Ratio (PE Ratio)?
Decision Diagnostics PE Ratio is now.
What was Decision Diagnostics earnings per share over the trailing 12 months (TTM)?
Decision Diagnostics EPS is -0.02 USD over the trailing 12 months.
Which sector does the Decision Diagnostics company belong to?
The Decision Diagnostics sector is Healthcare.